13th Asia-Pacific congress of clinical microbiology and infection consensus guidelines for diagnosis and treatment of liver failure

Hepatobiliary and Pancreatic Diseases International

Volumn 12, Issue 4, 2013, Pages 346-354

  Li, Lan Juan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; ALBUMIN; BILIRUBIN; ENDOTOXIN; ENTECAVIR; FUROSEMIDE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMIVUDINE; MANNITOL; NITRATE; NORADRENALIN; PENICILLIN G; PROTHROMBIN; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; SILYMARIN; SOMATOSTATIN DERIVATIVE; TELBIVUDINE; TENOFOVIR; TERLIPRESSIN; TOLVAPTAN; VASOPRESSIN;

ABDOMINAL DISTENSION; ACUTE KIDNEY FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ALLERGIC REACTION; ANOREXIA; ARTICLE; ARTIFICIAL LIVER; ASIA; BED REST; BLEEDING; BLEEDING TENDENCY; BRAIN EDEMA; CHRONIC LIVER FAILURE; ENTERIC FEEDING; FATIGUE; HEPATITIS B; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INTERNATIONAL NORMALIZED RATIO; INTESTINE FLORA; LIVER FAILURE; LIVER FIBROSIS; LIVER METABOLISM; LIVER NECROSIS; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PROGNOSIS; SECONDARY INFECTION; STEM CELL TRANSPLANTATION;

HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL;

EID: 84886402647     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(13)60055-7     Document Type: Article

References (40)

1. Polson J, Lee WM. American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-1197.
2. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi 2006;14:643-646.
3. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-282.
4. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012;55:965-967.
5. Deng G, Zhou G, Zhang R, Zhai Y, Zhao W, Yan Z, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008;134:716-726.
6. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-248.
7. Liu C, Wang YM, Fan K. Epidemiological and clinical features of hepatitis B virus related liver failure in China. World J Gastroenterol 2011;17:3054-3059.
8. Sun YL, Zhao JM, Zhou GD, Wang SS, Li WS, Meng EH, et al. Cut-off period of subclassifcation and pathological features of severe hepatitis based on clinical and pathological analyses. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2003;17:270-273.
9. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48:S2-19.
10. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844-853.
11. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
12. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991;303:1026-1029.
13. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988;319:1557-1562.
14. Sato RL, Wong JJ, Sumida SM, Marn RY, Enoki NR, Yamamoto LG. Efficacy of superactivated charcoal administered late (3 hours) after acetaminophen overdose. Am J Emerg Med 2003; 21:189-191.
15. Moroni F, Fantozzi R, Masini E, Mannaioni PF. A trend in the therapy of Amanita phalloides poisoning. Arch Toxicol 1976;36:111-115.
16. Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983;2:183-195.
17. Broussard CN, Aggarwal A, Lacey SR, Post AB, Gramlich T, Henderson JM, et al. Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol 2001;96:3195-3198.
18. Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002;40:715-757.
19. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011;54:562-572.
20. Canalese J, Gimson AE, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982;23:625-629.
21. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. DigDis Sci 1991;36:1223-1228.
22. Muñoz SJ, Moritz MJ, Bell R, Northrup B, Martin P, Radomski J. Factors associated with severe intracranial hypertension in candidates for emergency liver transplantation. Transplantation 1993;55:1071-1074.
23. Diringer MN, Reaven NL, Funk SE, Uman GC. Elevated body temperature independently contributes to increased length of stay in neurologic intensive care unit patients. Crit Care Med 2004;32:1489-1495.
24. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol 2009;6:542-553.
25. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in peptic ulcer haemorrhage: a 'meta-analysis'. Aliment Pharmacol Ther 2000;14:1119-1126.
26. Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol 2005;42:365-370.
27. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002;26:103-110.
28. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartifcial liver in treating acute liver failure. Ann Surg 2004;239:660-670.
29. Millis JM, Cronin DC, Johnson R, Conjeevaram H, Conlin C, Trevino S, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 2002;74:1735-1746.
30. Li J, Zhang L, Xin J, Jiang L, Li J, Zhang T, et al. Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs. Hepatology 2012;56:1044-1052.
31. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 2011;54:820-828.
32. Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, et al. Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc 2008;40:1140-1144.
33. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for non-bioartifcial liver support system in the treatment of liver failure. Chin J Clin Infect Dis 2009;2:321-325.
34. Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res 2008;38:S52-S55.
35. Steadman RH, Van Rensburg A, Kramer DJ. Transplantation for acute liver failure: perioperative management. Curr Opin Organ Transplant 2010;15:368-373.
36. Rao HY, Guo F, Wei L. Introduction and comments on AASLD practice guidelines: diagnosis and treatment of acute liver failure and assessment of liver transplant patients. Zhonghua Gan Zang Bing Za Zhi 2006;14:154-156.
37. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012;14:479-487.
38. McCaughan GW. Prevention of post liver transplant HBV recurrence. Hepatol Int 2011;5:876-881.
39. García-Pajares F, Almohalla C, Lorenzo Pelayo S, Ruiz Zorrilla R, Pinto P, Ramos C, et al. Early and extended therapy for recurrent hepatitis C after liver transplantation. Transplant Proc 2012;44:1571-1573.
40. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013;57:1752-1762.